FORM 6-K
 
 
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
 
the Securities Exchange Act of 1934
 
For the month of June 2017
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
 
 
1 Francis Crick Avenue
 
Cambridge Biomedical Campus
 
Cambridge CB2 0AA
 
 United Kingdom
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X            Form 40-F  __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):            
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes  __                 No X
 
 
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):   82-_____________
 
 
AstraZeneca PLC
 
INDEX TO EXHIBITS
 
 
1.
ASTRAZENECA PRICES A $2BN BOND ISSUE
 
 
 
 
6 June 2017 07:00 BST
 
 
 
ASTRAZENECA PRICES A $2BN BOND ISSUE
 
 
AstraZeneca PLC announces that, on 5 June 2017, it priced a three tranche Global bond offering totalling $2bn. The offering is expected to close on 12 June 2017, subject to customary closing conditions. AstraZeneca expects to use the net proceeds of the issue for general corporate purposes which may include the refinancing of existing indebtedness. The transaction, which is a global offering registered with the US Securities and Exchange Commission (SEC), consists of the following three tranches:
 
●     $1bn of 5 year fixed rate notes with a coupon of 2.375%;
●     $0.75bn of 10 year fixed rate notes with a coupon of 3.125%; and
●     $0.25bn of 5 year floating rate notes.
 
Barclays, BofA Merrill Lynch, HSBC and Morgan Stanley acted as joint-bookrunning managers on the transaction. The notes will be issued under AstraZeneca's effective shelf registration statement on Form F-3, which AstraZeneca filed with the SEC on 22 November 2016. The offering is being made solely by means of the prospectus contained within that shelf registration statement, along with a prospectus supplement forming part of the effective registration statement, which investors should read.
 
A copy of the prospectus supplement and accompanying prospectus relating to the offering can be obtained by contacting Barclays Capital Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-888-603-5847 or by email at barclaysprospectus@broadridge.com; HSBC Securities (USA) Inc., 452 Fifth Avenue, New York, NY 10018, Attention: Transaction Management Group, by telephone at 1-866-811-8049; Merrill Lynch, Pierce, Fenner & Smith Incorporated, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attention: Prospectus Department, by telephone at 1-800-294-1322 or by email at dg.prospectus_requests@baml.com; or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at 1-866-718-1649 or by email at prospectus@morganstanley.com. You may also download these documents for free by visiting EDGAR on the SEC website at www.sec.gov.
 
This announcement shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
 
The bond issuance does not impact the Company's financial guidance for 2017.
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
 
Cautionary Statements Regarding Forward-Looking Statements
This announcement contains certain forward-looking statements with respect to the operations, performance and financial condition of AstraZeneca. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this announcement and AstraZeneca undertakes no obligation to update these forward-looking statements.
 
Media Relations
 
 
 
Esra Erkal-Paler
 
UK/Global
 
+44 203 749 5638
 
Karen Birmingham
 
UK/Global
 
+44 203 749 5634
 
Rob Skelding
 
UK/Global
 
+44 203 749 5821
 
Jacob Lund
 
Sweden
 
+46 8 553 260 20
 
Michele Meixell
 
US
 
+1 302 885 2677
 
Investor Relations
 
 
 
Thomas Kudsk Larsen
 
 
+44 203 749 5712
 
Craig Marks
 
Finance, Fixed Income, M&A
 
+44 7881 615 764
 
Henry Wheeler
 
Oncology
 
+44 203 749 5797
 
Mitchell Chan
 
Oncology
 
+1 240 477 3771
 
Lindsey Trickett
 
Cardiovascular & Metabolic Diseases
 
+1 240 543 7970
 
Nick Stone
 
Respiratory
 
+44 203 749 5716
 
Christer Gruvris
 
Autoimmunity, Neuroscience & Infection
 
+44 203 749 5711
 
US toll free
 
 
+1 866 381 7277
 
 
Adrian Kemp
Company Secretary, AstraZeneca PLC
 
SIGNATURES
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
AstraZeneca PLC
 
Date: 06 June 2017
By:  /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary